Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-γ production and local IgA response

Tomoda, Takashi; Morita, Hideo; Kurashige, Takanobu; Maassab, Hunein F.

doi:10.1016/0264-410x(95)93134-u

Cited by 56 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the presence of a certain level of serum HAI antibody response is predictive of protection, the absence of such responses following LAIV administration does not correlate with lack of protection, as high levels of efficacy and effectiveness occur with low serum HAI responses elicited by LAIV (41). The explanation for this imperfect correlation between serum antibody and protection may be because LAIV induces protection through other mechanisms, such as by stimulating mucosal immune responses in the respiratory tree (20)(21)(22). While efficacy of any type of influenza vaccine in HIV-infected children remains unproven, we observed that the relative antibody responses to LAIV and TIV in HIV-infected children were similar to those reported in children without HIV infection (42,43).…”

Section: Discussionmentioning

confidence: 99%

“…Intranasal administration of LAIV simplifies immunization and avoids the pain of intramuscular injection, thereby making LAIV more acceptable to most patients and avoiding missed opportunities because of deferred administration. Moreover, because of intranasal administration, LAIV has the potential to stimulate greater local anti-influenza immune responses than TIV (20)(21)(22). LAIV demonstrated greater reductions in influenza than TIV in HIV-uninfected children, against strains that were well-matched with strains in the vaccine, as well as against antigenically drifted strains not included in the vaccine administered (23)(24)(25)(26)(27)(28), and several studies have shown that the LAIV protective effect can extend beyond the year of administration (27,28).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Levin

Song

Fenton

et al. 2008

Vaccine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Levin

Song

Fenton

et al. 2008

Vaccine

View full text Add to dashboard Cite

show abstract

“…For human influenza virus, the efficacy of several, so-called nasal vaccines have been extensively evaluated. A cold-adapted, live attenuated nasal influenza virus vaccine was confirmed to be safe and efficacious in humans because of the induction of secretory nasal IgA (sIgA) as well as IFN-γ production by specific CD4+ T-cells, even though only a low specific IgG response in serum was observed [29]. Intranasal vaccination with an inactivated trivalent influenza vaccine was also shown to be effective in humans and was able to induce both mucosal sIgA, as well as serum IgG immunologic responses [30].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza

Rosas

Walle

Metzger

et al. 2008

Vaccine

View full text Add to dashboard Cite

In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and is closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/ 10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical disease induced by CIV and can significantly reduce spread.

show abstract

“…Current human vaccines are inactivated vaccines that reduce Clinical trials of cold-adapted live attenuated vaccines have generated promising results with respect to both efficacy and safety (1,2,3,4,8,19,25,32,38,44). However, a molecular basis for the attenuation of the master vaccine strain of influenza B viruses remains unknown.…”

Section: Discussionmentioning

confidence: 99%

The NB Protein of Influenza B Virus Is Not Necessary for Virus Replication In Vitro

Hatta

Kawaoka

2003

J Virol

View full text Add to dashboard Cite

The NB protein of influenza B virus is thought to function as an ion channel and therefore would be expected to have an essential function in viral replication. Because direct evidence for its absolute requirement in the viral life cycle is lacking, we generated NB knockout viruses by reverse genetics and tested their growth properties both in vitro and in vivo. Mutants not expressing NB replicated as efficiently as the wild-type virus in cell culture, whereas in mice they showed restricted growth compared with findings for the wild-type virus. Thus, the NB protein is not essential for influenza B virus replication in cell culture but promotes efficient growth in mice.The genome of Influenza B virus, a member of the family Orthomyxoviridae, consists of eight negative-strand RNA segments, which encode 11 proteins. Of these, nine are also found in influenza A virus: three RNA-dependent RNA polymerase subunits (PB1, PB2, and PA), hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), matrix protein (M1), and two nonstructural proteins (NS1 and NS2). Two proteins, NB and BM2, are unique to influenza B virus. NB is encoded by RNA segment 6, which also encodes NA, while BM2 is encoded by segment 7.The NB protein of influenza B virus is a type III integral membrane protein, expressed abundantly on the surface of virus-infected cells (5,30,31), and is incorporated into virions (5, 7). This small protein (100 amino acids) possesses an 18-residue N-terminal ectodomain, a 22-residue transmembrane domain, and a 60-residue cytoplasmic tail (5, 42). From previous studies measuring membrane currents and by analogy with the M2 protein of influenza A virus (12,13,35), NB is thought to function as an ion channel protein. However, the electrophysiological measurements of the NB protein based on the lipid bilayer system are difficult to interrupt. That is, proteins and peptides containing hydrophobic domains, which are believed to lack ion channel activity in cells, can yield channel recordings in lipid bilayers (22,39,40). Moreover, in the studies of Fischer et al. (13) and Sunstrom et al. (35), amantadine was used to demonstrate the loss of channel activity by the NB protein, despite the inability of this drug to inhibit influenza B virus replication. Thus, the available evidence challenges the notion that the NB protein has ion channel activity.Recently, members of our group and others (14, 16, 23) established a reverse genetics system for generating influenza A virus entirely from cloned cDNAs, based on the in vivo synthesis of viral RNA. This innovation led us to devise a similar system to determine the importance of the NB protein in the life cycle of influenza B virus (Hoffmann et al. [17] and Jackson et al. [20] reported a reverse-genetics strategy for influenza B virus while this report was being prepared). Here, we generated influenza B virus NB knockout viruses by reverse genetics and tested their growth characteristics and other properties both in cell culture and in mice. MATERIALS AND METHODSCells, viruses, and...

show abstract

Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-γ production and local IgA response

Cited by 56 publications

References 32 publications

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza

The NB Protein of Influenza B Virus Is Not Necessary for Virus Replication In Vitro

Contact Info

Product

Resources

About